Scarica l'app Stockscreener
3.80
7.34%
0.26
Dopo l'orario di chiusura:
3.83
0.03
+0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.54
Aprire:
$3.66
Volume 24 ore:
686.09K
Relative Volume:
1.33
Capitalizzazione di mercato:
$89.73M
Reddito:
$156.31M
Utile/perdita netta:
$-245.76M
Rapporto P/E:
-0.2714
EPS:
-14
Flusso di cassa netto:
$-234.16M
1 W Prestazione:
+6.44%
1M Prestazione:
+38.69%
6M Prestazione:
-37.09%
1 anno Prestazione:
-71.52%
Intervallo 1D:
$3.55
$4.10
Intervallo di 1 settimana:
$3.39
$4.10
Portata 52W:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Confronta AGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.80 | 89.73M | 156.31M | -245.76M | -234.16M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development - Galveston County Daily News
William Blair Issues Optimistic Estimate for Agenus Earnings - MarketBeat
Agenus reports promising sarcoma study results - MSN
Game-Changing Cancer Treatment: New Drug Combo Keeps Patients Alive Nearly 2 Years Longer - StockTitan
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data - Endpoints News
Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright - Defense World
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewswire Inc.
Agenus reports promising colorectal cancer treatment data - MSN
Barclays PLC Buys 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus reports promising colorectal cancer treatment data By Investing.com - Investing.com UK
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease - The Bakersfield Californian
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - Morningstar
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Cervical Cancer Market Expected to Experience Major Growth - openPR
What Makes Agenus (AGEN) a New Buy Stock - Yahoo Finance
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Stock Holdings Lessened by Jane Street Group LLC - Defense World
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts - MarketBeat
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease - GlobeNewswire
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, VaccineGlobal Forecast to 2029 with GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agenus, Dynavax Technologies Dominating - Yahoo Finance UK
Barclays PLC Purchases 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
State Street Corp Boosts Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in December - MarketBeat
HighTower Advisors LLC Boosts Holdings in Agenus Inc. (NASDAQ:AGEN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Inve - GuruFocus.com
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Business Wire
Agenus to Present Groundbreaking Colorectal Cancer Treatment Data at ASCO GI Symposium - StockTitan
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
BNP Paribas Financial Markets Acquires 37,866 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Agenus Inc. Class Action: The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - Kilgore News Herald
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationAGEN - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Victoria Advocate
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus - BioSpace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) should contact The Gross Law Firm about pending Class Action - Longview News-Journal
HC Wainwright Has Optimistic Outlook of Agenus Q4 Earnings - MarketBeat
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Q1 Earnings Forecast for Agenus Issued By HC Wainwright - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
Walleye Capital LLC Acquires New Holdings in Agenus Inc. (NASDAQ:AGEN) - MarketBeat
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):